Karyopharm Therapeutics Inc. – NASDAQ:KPTI

Add to watchlist

$6.2

+5.49

+784.45%

Market closed

Open in about 11 hours

-25.70%

month

-25.70%

quarter

-24.09%

year

Market Cap	80.67M
Enterprise value	384.46M

P/E	-1.96
EV/Sales	2.44
EV/EBITDA	-2.74
Price/Sales	2.16
Price/Book	-20.44
PEG ratio	0.08
EPS	-1.27

Revenue	140.46M
EBITDA	-126.46M
Income	-146.33M
Revenue Q/Q	-14.39%
Revenue Y/Y	-5.15%

Profit margin	-105.23%
Oper. margin	-90.53%
Gross margin	96.68%
EBIT margin	-90.53%
EBITDA margin	-90.03%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Profit margin
Jun 2023	37.57M	-32.63M	-86.83%
Sep 2023	36.00M	-34.50M	-95.83%
Dec 2023	33.74M	-41.83M	-123.97%
Mar 2024	33.12M	-37.36M	-112.79%

Karyopharm Therapeutics Financials Estimate

Q Y

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Analyst Estimates
Mar 2024	33.12M	-37.36M	-112.79%
Sep 2025	46.70M	-30.99M	-66.36%
Oct 2025	46.70M	-32.32M	-69.22%
Dec 2025	49.62M	-25.39M	-51.19%

Analysts Price target
Financials & Ratios estimates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Debt to assets
Jun 2023	297830000	369.07M	123.92%
Sep 2023	269960000	370.35M	137.19%
Dec 2023	240438000	376.64M	156.65%
Mar 2024	204458000	373.41M	182.64%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Cash Flow
Jun 2023	-25.69M	21.17M	860K
Sep 2023	-29.53M	-7.68M	38.56M
Dec 2023	-18.58M	26.84M	264K
Mar 2024	-43.72M	21.94M	0

Karyopharm Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Karyopharm Therapeutics
Employees

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Employee count
Aug 2023	385
Sep 2023	385
Oct 2023	385
Nov 2023	385
Dec 2023	385
Jan 2024	385
Feb 2024	385
Mar 2024	325
Apr 2024	325
May 2024	325
Jun 2024	325
Jul 2024	325

Karyopharm Therapeutics
Hedge Funds Holdings Q3 2022

66.51% -20.05%

of KPTI is owned by hedge funds

128 -15

hedge funds hold KPTI stock

52.97M -14.16M

shares is hold by hedge funds

KPTI hedge funds holdings changes

Karyopharm Therapeutics
Insider Trading

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	4114
Feb 2024	0	195557
Mar 2024	0	49918
Apr 2024	0	10352
May 2024	0	207970
Jun 2024	0	1294764
Jul 2024	0	6499
Aug 2024	0	3608
Sep 2024	0	20044
Oct 2024	0	3607
Nov 2024	0	3675
Dec 2024	0	3620

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	4 Dec 2024	PAULSON RICHARD A. director, officer: President and CEO director, officer: President an..	Common Stock	3,620	$0.81	$2,932
Sale	5 Nov 2024	PAULSON RICHARD A. director, officer: President and CEO director, officer: President an..	Common Stock	3,675	$0.91	$3,348
Sale	4 Oct 2024	PAULSON RICHARD A. director, officer: President and CEO director, officer: President an..	Common Stock	3,607	$0.88	$3,171
Sale	4 Sep 2024	MANO MICHAEL officer: SVP, General Counsel&Secretary officer: SVP, General Counsel&S..	Common Stock	3,971	$0.72	$2,867
Sale	4 Sep 2024	PAULSON RICHARD A. director, officer: President and CEO director, officer: President an..	Common Stock	3,667	$0.72	$2,648
Sale	4 Sep 2024	MASON MICHAEL officer: EVP, CFO & Treasurer officer: EVP, CFO & Treasurer	Common Stock	7,050	$0.72	$5,090
Sale	4 Sep 2024	CHENG SOHANYA ROSHAN officer: EVP & Chief Commercial Officer officer: EVP & Chief Commercial..	Common Stock	5,356	$0.72	$3,867
Sale	6 Aug 2024	PAULSON RICHARD A. director, officer: President and CEO director, officer: President an..	Common Stock	3,608	$0.93	$3,355
Sale	30 Jul 2024	POULTON STUART officer: EVP, Chief Development Officer officer: EVP, Chief Development..	Common Stock	2,883	$1.06	$3,056
Sale	5 Jul 2024	PAULSON RICHARD A. director, officer: President and CEO director, officer: President an..	Common Stock	3,616	$0.85	$3,077

KPTI insider trading transactions

Karyopharm Therapeutics
Patents

Status	Patent	Filling date	Issue date
Application	Application PROCESS FOR PREPARING XPO1 INHIBITORS AND INTERMEDIATES FOR USE IN THE PREPARATION OF XPO1 INHIBITORS Filling date: 1 May 2020 Issue date: 4 Aug 2022	1 May 2020	4 Aug 2022
Application	Application NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Filling date: 23 Aug 2021 Issue date: 9 Jun 2022	23 Aug 2021	9 Jun 2022
Application	Application BIOMARKERS FOR SELINEXOR Filling date: 27 Mar 2020 Issue date: 9 Jun 2022	27 Mar 2020	9 Jun 2022
Application	Application IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY Filling date: 6 Jul 2021 Issue date: 2 Jun 2022	6 Jul 2021	2 Jun 2022
Application	Application POLYMORPHS OF SELINEXOR Filling date: 1 Jul 2021 Issue date: 5 May 2022	1 Jul 2021	5 May 2022
Application	Application HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Filling date: 14 May 2021 Issue date: 10 Mar 2022	14 May 2021	10 Mar 2022
Application	Application NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Filling date: 4 May 2021 Issue date: 24 Feb 2022	4 May 2021	24 Feb 2022
Application	Application SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Filling date: 18 Mar 2021 Issue date: 30 Dec 2021	18 Mar 2021	30 Dec 2021
Application	Application THE COMBINATION OF XPO1 INHIBITORS AND SECOND AGENTS FOR THE TREATMENT OF PROSTATE CANCER Filling date: 5 Sep 2019 Issue date: 14 Oct 2021	5 Sep 2019	14 Oct 2021
Grant	Grant Utility: Nuclear transport modulators and uses thereof Filling date: 23 Jul 2019 Issue date: 21 Sep 2021	23 Jul 2019	21 Sep 2021

KPTI patents

Karyopharm Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 29 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

KPTI earnings call transcripts

Karyopharm Therapeutics
Executives

Insider	Age	Compensation
Dr. Michael G. Kauffman M.D., Ph.D. (1963) Co-Founder, Senior Clinical Advisor & Director	62	$986,250
Dr. Sharon Shacham (1970) Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board	55	$720,100
Mr. Michael P. Mason CPA, M.B.A. (1975) Senior Vice President, Chief Financial Officer & Treasurer	50	$583,630
Dr. Mansoor Raza Mirza (1961) Clinical Consultant, Member of Scientific Advisory Board & Director	64	$140,600
Mr. Richard A. Paulson M.B.A. (1967) Pres, Chief Executive Officer & Director	58	$52,380

Karyopharm Therapeutics
Latest News

Monday, 9 December 2024
08:00	Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications	prnewswire.com
Tuesday, 3 December 2024
07:00	Karyopharm Therapeutics Provides Endometrial Cancer Program Update	prnewswire.com
Monday, 2 December 2024
07:00	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Monday, 25 November 2024
07:00	Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference	prnewswire.com
Wednesday, 20 November 2024
16:05	Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer	prnewswire.com
Monday, 18 November 2024
07:00	Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition	prnewswire.com
Tuesday, 5 November 2024
21:22	Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript	seekingalpha.com
19:30	Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024	prnewswire.com
09:41	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
07:30	Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress	prnewswire.com
Friday, 1 November 2024
16:05	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Thursday, 31 October 2024
11:05	Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release	zacks.com
08:00	Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024	prnewswire.com
07:30	Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis	prnewswire.com
Wednesday, 30 October 2024
16:30	Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024	prnewswire.com
Thursday, 17 October 2024
22:35	Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country	prnewswire.com
Tuesday, 1 October 2024
16:05	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Monday, 23 September 2024
05:00	Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand	prnewswire.com
Thursday, 5 September 2024
10:35	Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround	zacks.com
Tuesday, 3 September 2024
16:05	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
07:00	Karyopharm to Participate at Upcoming Investor Conferences	prnewswire.com
Tuesday, 6 August 2024
10:25	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
07:30	Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress	prnewswire.com
Monday, 5 August 2024
20:00	Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia	prnewswire.com
Thursday, 1 August 2024
16:05	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Wednesday, 31 July 2024
16:05	Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024	prnewswire.com
Friday, 5 July 2024
09:10	XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country	prnewswire.com
Monday, 1 July 2024
16:05	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Wednesday, 26 June 2024
04:42	Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea	prnewswire.com
Monday, 3 June 2024
16:05	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com

Ideas & Opinions

Seeking Alpha 30 Apr 2024

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts
Seeking Alpha 5 Feb 2024

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Seeking Alpha 29 Nov 2023

Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky
Seeking Alpha 20 Mar 2023

Karyopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma Market
Seeking Alpha 29 Dec 2022

Karyopharm: Recent Sell-Off Hits A New Buy Target
Seeking Alpha 7 Oct 2022

Karyopharm: Market Is Overlooking Growth
Seeking Alpha 5 May 2022

Karyopharm: Another 2 Year Wait For Data
Seeking Alpha 19 Feb 2022

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates
Seeking Alpha 4 Dec 2021

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position
Seeking Alpha 16 Sep 2021

Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls

Frequently Asked Questions (FAQ)

What's the price of Karyopharm Therapeutics stock today?

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $6.2.
When is Karyopharm Therapeutics's next earnings date?

Unfortunately, Karyopharm Therapeutics's (KPTI) next earnings date is currently unknown.
Does Karyopharm Therapeutics pay dividends?

No, Karyopharm Therapeutics does not pay dividends.
How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics has a market capitalization of 80.67M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 7.03% to 146.03M US dollars.
What is Karyopharm Therapeutics's stock symbol?

Karyopharm Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "KPTI".
What is Karyopharm Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Karyopharm Therapeutics?

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Karyopharm Therapeutics's key executives?
Karyopharm Therapeutics's management team includes the following people:
- Dr. Michael G. Kauffman M.D., Ph.D. Co-Founder, Senior Clinical Advisor & Director(age: 62, pay: $986,250)
- Dr. Sharon Shacham Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board(age: 55, pay: $720,100)
- Mr. Michael P. Mason CPA, M.B.A. Senior Vice President, Chief Financial Officer & Treasurer(age: 50, pay: $583,630)
- Dr. Mansoor Raza Mirza Clinical Consultant, Member of Scientific Advisory Board & Director(age: 64, pay: $140,600)
- Mr. Richard A. Paulson M.B.A. Pres, Chief Executive Officer & Director(age: 58, pay: $52,380)
Is Karyopharm Therapeutics founder-led company?

Yes, Karyopharm Therapeutics is a company led by its founders Dr. Michael G. Kauffman M.D., Ph.D. and Dr. Sharon Shacham.
How many employees does Karyopharm Therapeutics have?

As Jul 2024, Karyopharm Therapeutics employs 325 workers.
When Karyopharm Therapeutics went public?

Karyopharm Therapeutics Inc. is publicly traded company for more then 11 years since IPO on 6 Nov 2013.
What is Karyopharm Therapeutics's official website?

The official website for Karyopharm Therapeutics is karyopharm.com.
Where are Karyopharm Therapeutics's headquarters?

Karyopharm Therapeutics is headquartered at 85 Wells Avenue, Newton, MA.
How can i contact Karyopharm Therapeutics?

Karyopharm Therapeutics's mailing address is 85 Wells Avenue, Newton, MA and company can be reached via phone at +61 76580600.

Karyopharm Therapeutics Inc.

karyopharm.com

Exchange:

NASDAQ

Full time employees:

325

Industry:

Biotechnology

Sector:

Healthcare

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

+61 76580600

85 Wells Avenue
Newton, MA 02459

CIK: 0001503802
ISIN: US48576U1060
CUSIP: 48576U106